Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for CLLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -417.3%
March 31, 2026 -307.5%
December 31, 2025 -253.1%
September 30, 2025 1.67%
June 30, 2025 -141.9%
March 31, 2025 -170.1%
December 31, 2024 46.57%
September 30, 2024 -142.3%
June 30, 2024 -313.5%
March 31, 2024
December 31, 2023 -22.48K%
September 30, 2023 -11.28K%
June 30, 2023 -16.70K%
March 31, 2023 -20.02K%
December 31, 2022 -160.4%
September 30, 2022 -14.60K%
June 30, 2022 -1.45K%
March 31, 2022 -1.70K%
December 31, 2021 -230.1%
September 30, 2021 -482.1%
June 30, 2021 -372.3%
March 31, 2021 -59.94%
December 31, 2020 -327.0%
Date Value
September 30, 2020 -543.8%
June 30, 2020 -1.24K%
March 31, 2020 33.12%
December 31, 2019 -930.5%
September 30, 2019 -229.6%
June 30, 2019 -3.18K%
March 31, 2019 -1.71K%
December 31, 2018 -2.69K%
September 30, 2018 -2.79K%
June 30, 2018 -192.9%
March 31, 2018 -447.6%
December 31, 2017 -501.7%
September 30, 2017 -475.3%
June 30, 2017 -408.1%
March 31, 2017 -293.4%
December 31, 2016 -164.1%
September 30, 2016 -124.8%
June 30, 2016 -39.53%
March 31, 2016 -422.2%
December 31, 2015 30.54%
September 30, 2015 -168.0%
June 30, 2015 -302.5%
March 31, 2015 74.94%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
DBV Technologies SA --
Akari Therapeutics Plc --
EDAP TMS SA -109.2%
Autolus Therapeutics Plc -85.60%
Evaxion AS --